|
Protocol 09-22-H-05: "A Randomized, Double-Blind, Controlled, Parallel Group, 12-Week Treatment Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150µg Once Daily with Open Label Triotropium 18µg Once Daily Versus Open Label Tiotropium 18µg Once Daily in Patients with Moderate to Severe Chronic Obstructive Pulmonary DiseaseIf you have been diagnosed with Chronic Obstructive Pulmonary Disease, you may be a candidate for this clinical research study"
The Pulmonary and Critical Care Division at Mount Sinai Medical Center is conducting a clinical research study to compare the safety and effectiveness of the once daily combination of inhaled Indaceterol (an investigational drug) and tiotropium (an approved drug) with open label tiotropium alone in patients with Chronic Obstructive Pulmonary Disease (COPD).
We are currently screening patients with Chronic Obstructive Pulmonary Disease who are over 40 years of age and have a history of smoking. If you qualify, you will receive at no cost:
- Investigational medication
- Study-related office visits
- Study related physical exams and tests
You will also receive financial compensation for your time and travel.
For more information about these research studies please contact:
Ignacio Danta at (305) 674-2716
Protocol 09-44-H-11 "A 24-Week Randomized Placebo-Controlled, Double-Blind, Multi-Center Clinical Trial Evaluating the Efficacy and Safety of Oral QT1571 as an Add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)"
If you are currently being treated for severe pulmonary hypertension, you may be a candidate for this clinical research study
The Pulmonary and Critical Care Division at Mount Sinai Medical Center is conducting a clinical research study to compare the safety and effectiveness of oral QTI-571 (Imatinib) as an add-on therapy in the treatment of severe pulmonary hypertension. We are currently screening patients with severe pulmonary hypertension (18 years of age or older) who remain symptomatic on at least two drugs specific for pulmonary hypertension.
If you qualify, you will receive at no cost:
- Investigational medication
- Study-related office visits
- Study related physical exams and tests
For more information about these research studies please contact:
Ignacio Danta at (305) 674-2716
If you are currently being treated for severe pulmonary hypertension, you may be a candidate for this clinical research study"
|
